Focada exclusivamente no desenvolvimento, 
                                        produção e promoção de produtos farmacêuticos especializados

Material Fact – Launching Of Tender Offer

Corporate Taxpayer’s ID (CNPJ/ME): 19,688,956/0001-56
L-1470 Luxembourg, 70 route d’Esch, Grand-Duché de Luxembourg
Legal representative in Brazil: Av. dos Imarés, 401, São Paulo, SP



BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical company in Latin America, hereby informs its shareholders and the market in general, following the material fact disclosed by the Company on July 8, 2020 that, on the date hereof, 11718991 Canada Inc. (the “Offeror”), a wholly owned subsidiary of Knight Therapeutics Inc., has launched the tender offer and released the notice of the unified tender offer for the acquisition of BDRs representing shares of the Company , aiming at (i) fulfilling the Offeror’s statutory obligation to conduct a public offer for the acquisition of the outstanding BDRs following the transfer of control (“Tag Along Tender Offer”); and
(ii) the voluntary discontinuity of the BDRs program of the Company (“Discontinuity of the BDR Program” and, together with the Tag Along Tender Offer, the “Tender Offer”), in compliance with applicable regulation.
BDR holders are invited to tender their BDRs at the auction that will take place on August 14th, 2020.

The notice of the Tender Offer, containing detailed information on the terms and conditions of the Tender Offer, and the other documents relating to the Tender Offer, are available in the IPE System of CVM ( and B3 S.A. – Brasil, Bolsa, Balcão (, and in the website of GBT ( and the Intermediary Institution ( pt/nossos-negocios/ofertas-publicas).
The Company will keep its shareholders and the market informed on the developments of the events mentioned in this material fact, in compliance with applicable regulation.

Montevideo, July 15, 2020

Claudio Coracini
Legal Representative in Brasil

Updated on 07/15/2020 at 12:33 pm